SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

Given the multi-faceted pathogenesis of atherosclerosis in type 2 diabetes mellitus (T2DM), it is likely that interventions to mitigate this risk must address cardiovascular (CV) risk factors beyond glucose itself. Sodium glucose cotransporter-2 (SGLT-2) inhibitors are newer antihyperglycaemic agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Inzucchi, Silvio E, Zinman, Bernard, Wanner, Christoph, Ferrari, Roberto, Fitchett, David, Hantel, Stefan, Espadero, Rosa-Maria, Woerle, Hans-Jürgen, Broedl, Uli C, Johansen, Odd Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361459/
https://www.ncbi.nlm.nih.gov/pubmed/25589482
http://dx.doi.org/10.1177/1479164114559852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361459/
https://www.ncbi.nlm.nih.gov/pubmed/25589482
http://dx.doi.org/10.1177/1479164114559852

Ejemplares similares